BIOGEN INC.
For the period ended Sep 30, 2026. Filed Oct 28, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
ITEM 5. OTHER INFORMATION
TRADING ARRANGEMENTS
From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into, amend or terminate Rule 10b5-1 ornon-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the third quarter of 2026, there were no trading arrangements for the purchase or sale of our securities entered into, amended or terminated by our officers and directors.
In our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, we reported that on May 4, 2026, Lloyd Minor, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 593 shares of our common stock. The correct aggregate number of shares covered by such Rule 10b5-1 trading arrangement was 1,186 shares of our common stock. All other terms of Mr. Minor's previously disclosed Rule 10b5-1 trading arrangement remain as previously described.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.